一月 2026
- Home
- Jazz Pharmaceuticals
一月 2026的Jazz Pharmaceuticals市场份额分析
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States.
Jazz Pharmaceuticals(包含公司地区分支机构)
查看更多网站流量和参与度信息- jazzpharma.com
Jazz Pharmaceuticals收入截至 一月 2026为 > 1B
Jazz Pharmaceuticals主要域名产生的收入
3 年中Jazz Pharmaceuticals主要域名的收入
Jazz Pharmaceuticals主要域名的收入
Jazz Pharmaceuticals热门域名的总访问量
了解Jazz Pharmaceuticals市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Jazz Pharmaceuticals热门域名的平均访问时长
分析Jazz Pharmaceuticals参与度指标。
过去 3 个月的平均访问时长
子公司明细
Jazz Pharmaceuticals热门域名的平均页面浏览量
了解Jazz Pharmaceuticals如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Jazz Pharmaceuticals 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Jazz Pharmaceuticals, Inc. is developing zanidatamab in different territories.Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric(TM) technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories.
一月 27, 2026阅读更多
新闻Boehringer Ingelheim partnered with Jazz Pharmaceuticals, Inc. on Jan 12th '26.Boehringer Ingelheim today announced a strategic clinical collaboration with Jazz Pharmaceuticals (Nasdaq: JAZZ) on the exploration of a novel combination therapy for patients with HER2-positive breast cancer.
一月 12, 2026阅读更多
新闻Jazz Pharmaceuticals, Inc. launches data for zanidatamab in HER2-positive gastric cancer.Jazz Pharma announced "practice-changing" data for zanidatamab in HER2-positive gastric cancer.
一月 1, 2026阅读更多
查看 Jazz Pharmaceuticals 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。